Premium
The Impact of Thyroid Disease on the Regulation, Expression, and Function of ABCB1 (MDR1/P Glycoprotein) and Consequences for the Disposition of Digoxin
Author(s) -
Burk O,
Brenner S S,
Hofmann U,
Tegude H,
Igel S,
Schwab M,
Eichelbaum M,
Alscher M D
Publication year - 2010
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.176
Subject(s) - digoxin , p glycoprotein , thyroid , endocrinology , medicine , thyroid function , efflux , disposition , hormone , bioavailability , thyroid disease , rhodamine 123 , pharmacokinetics , pharmacology , chemistry , biochemistry , heart failure , social psychology , psychology , multiple drug resistance , antibiotics
The impact of thyroid dysfunction on the regulation, expression, and function of ABCB1 remains unclear. We therefore investigated ABCB1 mRNA expression and function in patients with thyroid dysfunction and studied the disposition of the ABCB1 substrate digoxin before and after treatment for thyroid disease. In patients with hypothyroidism, normalization of thyroid function was associated with a 1.8‐fold increase in mRNA expression and a 26% increase in rhodamine efflux from CD56 + cells. In hypothyroidism, digoxin clearance was significantly decreased, whereas bioavailability, volume of distribution, half‐life time, and protein binding were unaltered. In hyperthyroidism, ABCB1 mRNA expression, rhodamine efflux, and disposition of digoxin were not significantly affected other than in relation to renal clearance. Experiments using the LS174T cell line indicated that the gene is a direct target of thyroid hormone receptors. In conclusion, thyroid abnormalities can exert significant effects on the expression of P‐glycoprotein, thereby altering the disposition and action of drugs that are substrates of P‐glycoprotein. Clinical Pharmacology & Therapeutics (2010) 88 5, 685–694. doi: 10.1038/clpt.2010.176